Author:
Hui Wen,Gao Zhixiang,Zhu Min,Wu Huazhang,Cai Yuanyi
Abstract
AbstractIn this article, we read with great attention the correspondence by Bullement et al., regarding our published study on cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer. We referred to a few the most important comments from Bullement et al. in our opinion, including proportional hazard (PH) assumption, accelerated failure time (AFT) model, and health utility, and made some explanations.
Publisher
Springer Science and Business Media LLC
Reference11 articles.
1. Latimer N, Nice DSU technical support. document 14: Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data. https://www.sheffield.ac.uk/nice-dsu/tsds/full-list. Accessed 30Jan 2024.
2. Liu LH, Bai H, Wang C, Seery S, Wang ZJ, Duan JC, et al. Efficacy and safety of First-Line Immunotherapy combinations for Advanced NSCLC: a systematic review and network Meta-analysis. J Thorac Oncol. 2021;16(7):1099–117.
3. Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn M-J, et al. Durvalumab with or without Tremelimumab vs Standard Chemotherapy in First-line treatment ofMetastatic Non-small Cell Lung Cancer: the MYSTIC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6:661–74.
4. Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Med Res Methodol. 2011;11:61.
5. Wiksten A, Hawkins N, Piepho HP, Gsteiger S. Nonproportional hazards in network meta-analysis: efficient strategies for model building and analysis. Value Health. 2020;23(7):918–27.